Multicenter study reveals distinct fgfr fusion patterns in a Chinese cohort, suggesting novel strategies for targeted therapies.
Key Points
Our study reports a 0.96% incidence of fgfr rearrangements in a Chinese cohort, with 40% in parotid gland carcinoma, highlighting potential therapeutic targets.
Utilizing both DNA and RNA sequencing, we identified distinct fgfr fusion breakpoint patterns, revealing critical insights into the functionality and distribution of these fusions.
In our multicenter analysis, 46% of rare fgfr1/2/3 fusions lacked detectable RNA transcripts, underscoring the need for RNA-based validation in identifying actionable fgfr fusions.
The findings advocate for incorporating novel fusions in targeted sequencing efforts to improve detection and therapeutic strategies for fgfr-targeted therapies.